Inhibiteurs de JAK et risque de cancer

Gouverneur, Amandine; Avouac, Jérôme; Prati, Clément; Cracowski, Jean Luc; Schaeverbeke, T.; Pariente, A.; Truchetet, Marie-Élise

doi:10.1016/j.rhum.2022.10.094

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding cardiovascular SAEs, besides findings with tofacitinb in the Oral surveillance trial for RA [9], several RWD studies with JAKi have observed an increased risk of major adverse cardiovascular events (MACE) or thromboembolism in elderly patients with certain cardiovascular risk factors [53][54][55]. No MACE was recorded in our cohort and only one venous thrombotic event was observed, in line with standardized incidence rates described by Uchida et al [51] or in the metaanalysis by Salinas et al [53].…”

Section: Discussionsupporting

confidence: 89%

Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study

Calvo-Garcia,

Ramírez Herráiz,

Llorente Cubas

et al. 2024

Preprint

View full text Add to dashboard Cite

Background/Aim: Baricitinib (BAR) is the first oral selective Janus kinase inhibitor approved in Europe for rheumatoid arthritis (RA). Real-world data are still needed to clarify its long-term benefit/risk profile. This study aimed to evaluate the effectiveness, persistence, adherence, and safety of BAR in a real-world setting. Methods: An ambispective study was conducted between October 2017 and December 2021 in RA patients starting BAR. Effectiveness was evaluated by change from baseline in the Disease Activity Score using 28-joint counts-C reactive protein (DAS28CRP), and achievement of low disease activity/remission. Drug persistence was evaluated by Kaplan-Meier analysis. Adherence was estimated by medication possession ratio (MPR) and the 5-item Compliance Questionnaire for Rheumatology. Safety was assessed by global incidence proportion and adjusted incidence rates of adverse events. Results: 61/64 recruited patients were finally analyzed, 83.6% female, 78.7% seropositive, mean age of 58.1 (15.4) years, and disease duration of 13.9 (8.3) years. 32.8% were naïve to biologics and 16.4% received BAR on monotherapy. After a median exposure to BAR of 12.4 (6.6-31.2) months (range 3.1-51.4), a significant change in DAS28CRP was observed (difference -1.2, p=0.000). A total of 70.5% and 60.7% patients achieved low disease activity or remission, respectively and 50.8% (31/61) patients remained on BAR during follow-up with a median persistence of 31.2 (9.3-53.1) months. The average MPR was 0.96 (0.08) and all patients were “good adherents” by questionnaire. 21.3% patients discontinued baricitinib due to toxicity. Conclusion: In our real-world practice, BAR demonstrated effectiveness, large persistence, high adherence to treatment and acceptable safety profile.

show abstract

Section: Discussionsupporting

confidence: 89%

Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study

Calvo-Garcia,

Ramírez Herráiz,

Llorente Cubas

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Analysis of the Spanish registry, BIOBADASER 3.0, and the Argentinian registry, BIOBADASER 3.0, identified no increased risk of cancer in JAKi users compared with TNFi users [89,90]: a finding similar to that of a study using the SNDS administrative claims data [134]. Another study of administrative claims data investigating the association of tofacitinib and cancer led to similar observations [135].…”

Section: Jaki Safety From Rwementioning

confidence: 66%

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Taylor

Laedermann

Alten

et al. 2023

JCM

View full text Add to dashboard Cite

Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheumatoid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currently, baricitinib is approved for treating RA in more than 75 countries. In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. Safety signals for another JAK inhibitor, tofacitinib, have emerged, as observed in the post-marketing Phase IIIb/IV trial Oral Rheumatoid Arthritis Trial (ORAL) Surveillance; safety signals were subsequently highlighted in a retrospective study of baricitinib and consequently new recommendations and warnings and precautions for all JAK inhibitors have been issued. Ongoing studies to further characterise and clarify the benefit:risk of JAK inhibitors include registries and controlled trials. This capstone review summarises clinical and real-world data outlining the benefit:risk profile of baricitinib, confirming that the improved disease activity and physical function of patients with RA treated with this JAK inhibitor observed in clinical trials is translated into effectiveness in clinical practice, with a low rate of discontinuations.

show abstract

Inhibiteurs de JAK et risque de cancer

Cited by 2 publications

References 0 publications

Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study

Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

Contact Info

Product

Resources

About